The field of precision medicine has evolved rapidly
Incorporating precision medicine into routine clinical care has been challenging
Advances in precision diagnostics can make everyday precision medicine a reality1
References:
2. Pennell NA, et al. Economic impact of next-generation sequencing versus single-gene testing to detect genomic alterations in metastatic non–small-cell lung cancer using a decision analytic model. JCO Precis Oncol. 2019;3:1-9.
More >>>
More >>>
More >>>
References:
Can help ensure patients receive targeted therapy, which can improve outcomes1
Reference:
with comprehensive analysis of both hematologic and solid tumors
informed by an algorithm that is continually updated with new information as it becomes clinically relevant and validated
with actionable reporting
that can inform decision-making
in everyday practice
Dr. Albitar has extensive experience in anatomic/clinical pathology, hematopathology, and molecular pathology.
He also has extensive business and administrative experience as an executive leader of large laboratories, board member, and director of large scientific and genomic diagnostic studies.
Dr. Albitar’s previous experience also includes his position as Senior Vice President, Chief Medical Officer, and Director of Research and Development at NeoGenomics.
Dr. Ewing is Chair, Department of Pathology, and Medical Director of the Laboratories at JFK University Medical Center, where he has served since 2003.
Dr. Ewing received his B.S. degree from Davidson College in 1993, and his M.D. degree from Wake Forest University School of Medicine in 1997.
He completed his residency in Anatomic and Clinical Pathology at Georgetown University Hospital in Washington, DC, in 2001, also serving as Chief Resident.
• All types of genomic changes (single nucleotide variants, insertions/deletions, copy number variations, fusions)
• Detection of minimal residual disease
• Treatment selection
• Surveillance monitoring for early recurrence
Minimum sample requirements for comprehensive testing
• Bone marrow: 2 mL
• Fresh tissue: 5 microns
• Peripheral blood: 5 mL
• 7 days for DNA
• 10 days for RNA
• Customized treatment plans
• Confirmed by clinical pathologist
• Formalin-Fixed Paran-Embedded (FFPE)
• Peripheral blood
• Bone marrow
• Fresh tissue
• Expert team of pathologists dedicated to individual
treatment plans
• Physician-staed clinical support to help interpret
lab results
Making a
diagnosis
Identifying a
targeted treatment
Monitoring minimal
residual disease
Payers have potentially overlooked comprehensive genomic profiling as a sophisticated testing approach that informs complex clinical decision-making and enables a patient’s next best care option, be it drug therapy or no further treatment.
– Nesline MK, et al.
Reference:
Completed forms can be
Step 1: Understand the testing options
Step 2: Complete the test requisition form*
Step 3: Interpret the
final report
Your final report will include:
*Once this form is complete, Genomic Testing Cooperative will ship a Collection Kit for tumor sample collection if needed.
Current as of 7/11/2020